NHS National Generic Pharmaceuticals Transition 2021_1
A Contract Award Notice
by THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND)
- Source
- OJEU
- Type
- Framework (Supply)
- Duration
- 14.5 month (est.)
- Value
- £27M
- Sector
- HEALTH
- Published
- 04 May 2021
- Delivery
- 15 Apr 2021 to 30 Jun 2022 (est.)
- Deadline
- n/a
Concepts
Location
Please refer to Document 3, Schedule 8 in the ITO documents for the list of purchasing points
2 buyers
20 suppliers
- Ascend Laboratories Edgware
- Aspire Pharma Petersfield
- Brown & Burk Uxbridge
- Day Lewis Medical Croydon
- Martindale Pharma High Wycombe
- Panpharma Liverpool
- Aventis Pharma Reading
- Medac Pharma Sterling
- Aspen Pharma Ireland Maidenhead
- Kent Pharma Ashford
- Morningside Pharmaeuticals Loughborough
- Pfizer Tadworth
- Teva Castleford
- Tillomed Laboratories Luton
- Thornton & Ross Huddersfield
- Accord Barnstaple
- Amarox Harrow
- Drreddys Laboratories Beverley
- Selective Supplies Haywards Heath
- Ranbaxy Hayes
Description
Transition and 33 % products: CESW 15 April 2021 to 30 September 2021 (5.5 months); LSNE 15 April 2021 to 28 February 2022 (10.5 months); NWLN 15 April 2021 to 30 June 2022 (14.5 months); 100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months). The total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months).
Lot Division
| 1 | Transition 2021_1 — 100 % Products (All Regions) NHS National Pharmaceuticals Transition 2021_1 Offer reference number: CM/PHG/20/5629 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months) Potential Periods of call-offs under the framework agreement Transition and 33 % Products: CESW 15 April 2021 to 30 September 2021 (5.5 months); LSNE 15 April 2021 to 28 February 2022 (10.5 months); NWLN 15 April 2021 to 30 June 2022 (14.5 months); 100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months). |
| 2 | Transition 2021_1 — CESW Region (Transition and 33 % Products) NHS National Pharmaceuticals Transition 2021_1 Offer reference number: CM/PHG/20/5629 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months) Potential Periods of call-offs under the framework agreement Transition and 33 % Products: CESW 15 April 2021 to 30 September 2021 (5.5 months); LSNE 15 April 2021 to 28 February 2022 (10.5 months); NWLN 15 April 2021 to 30 June 2022 (14.5 months); 100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months). |
| 3 | Transition 2021_1 — LSNE Region (Transition and 33 % Products) NHS National Pharmaceuticals Transition 2021_1 Offer reference number: CM/PHG/20/5629 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months) Potential Periods of call-offs under the framework agreement Transition and 33 % Products: CESW 15 April 2021 to 30 September 2021 (5.5 months); LSNE 15 April 2021 to 28 February 2022 (10.5 months); NWLN 15 April 2021 to 30 June 2022 (14.5 months); 100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months) |
| 4 | Transition 2021_1 — NWLN Region (Transition and 33 % products) NHS National Pharmaceuticals Transition 2021_1 Offer reference number: CM/PHG/20/5629 Period of framework agreement: the total maximum duration of the framework agreement to be no more than 29 months (14.5 months plus options to extend (at the Authority's sole discretion) for up to a further 14.5 months) Potential Periods of call-offs under the framework agreement Transition and 33 % Products: CESW 15 April 2021 to 30 September 2021 (5.5 months); LSNE 15 April 2021 to 28 February 2022 (10.5 months); NWLN 15 April 2021 to 30 June 2022 (14.5 months); 100 % Products (All Regions): 15 April 2021 to 28 February 2022 (10.5 months). |
Award Detail
| 1 | Ascend Laboratories (Edgware)
|
| 2 | Aspire Pharma (Petersfield)
|
| 3 | Brown & Burk (Uxbridge)
|
| 4 | Day Lewis Medical (Croydon)
|
| 5 | Martindale Pharma (High Wycombe)
|
| 6 | Panpharma (Liverpool)
|
| 7 | Aventis Pharma (Reading)
|
| 8 | Medac Pharma (Sterling)
|
| 9 | Aspen Pharma Ireland (Maidenhead)
|
| 10 | Kent Pharma (Ashford)
|
| 11 | Aspire Pharma (Petersfield)
|
| 12 | Day Lewis Medical (Croydon)
|
| 13 | Morningside Pharmaeuticals (Loughborough)
|
| 14 | Pfizer (Tadworth)
|
| 15 | Teva (Castleford)
|
| 16 | Tillomed Laboratories (Luton)
|
| 17 | Thornton & Ross (Huddersfield)
|
| 18 | Accord (Barnstaple)
|
| 19 | Medac Pharma (Sterling)
|
| 20 | Amarox (Harrow)
|
| 21 | Drreddys Laboratories (Beverley)
|
| 22 | Aspen Pharma Ireland (Maidenhead)
|
| 23 | Morningside Pharmaeuticals (Loughborough)
|
| 24 | Teva (Castleford)
|
| 25 | Kent Pharma (Ashford)
|
| 26 | Panpharma (Liverpool)
|
| 27 | Pfizer (Tadworth)
|
| 28 | Selective Supplies (Haywards Heath)
|
| 29 | Accord (Barnstaple)
|
| 30 | Aspen Pharma Ireland (Maidenhead)
|
| 31 | Medac Pharma (Sterling)
|
| 32 | Drreddys Laboratories (Beverley)
|
| 33 | Kent Pharma (Ashford)
|
| 34 | Day Lewis Medical (Croydon)
|
| 35 | Morningside Pharmaeuticals (Loughborough)
|
| 36 | Panpharma (Liverpool)
|
| 37 | Pfizer (Tadworth)
|
| 38 | Ranbaxy (Hayes)
|
| 39 | Teva (Castleford)
|
Award Criteria
| PRICE | _ |
CPV Codes
- 33600000 - Pharmaceutical products
- 33690000 - Various medicinal products
Indicators
- Options are available.
- Award on basis of price.
Reference
- OJEU 223853-2021